Acceleron: When Bad News Is Really Good News

Acceleron has discontinued development of a kidney cancer after it failed in a clinical trial. Yet the drug maker's stock is on the rise today. Here's why.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.